Complete full study enrollment of 26 patients in AMT-130 trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 25 Oct 2021
- Due
- 30 Jun 2022
- Delivered
- 21 Mar 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Full study enrollment of all 26 patients is expected to be completed by mid-2022.”
What we found
Evidence strength A What the grades mean
The company announced on March 21, 2022, that it had completed the enrollment of all 26 patients in the U.S. Phase I/II clinical trial of AMT-130, meeting the mid-2022 deadline.
-
A uniQure N.V. 10-Q filed 2022-08-08
“On March 21, 2022, we announced that we have completed the enrollment of all 26 patients in the first two cohorts of our randomized, double-blinded, Phase I/II clinical trial of AMT-130 taking place in the U.S.” ✓ confirmed on the page
Market reaction: the shares moved -25.1% against the S&P 500 over the three sessions around the disclosure (5 Aug 2022 to 10 Aug 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- full study enrollment
- Target
- 26 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-001783 · Corrections policy